Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
Hamza Mohamed, Medical Director and Medical Resident St. Paulos MMH at Ethiopian Health professionals’ Associations, shared a post on LinkedIn:
“Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute Pulmonary Embolism (PE)
The 2026 AHA/ACC guideline represents the first comprehensive U.S. clinical practice guideline dedicated entirely to the evaluation and management of acute pulmonary embolism. It introduces several important practice-changing recommendations.
1. A new PE classification replaces ‘massive’ and ‘submassive’
The guideline introduces AHA/ACC Acute PE Clinical Categories (A–E), providing a more precise framework based on clinical severity, RV dysfunction, biomarkers, and hemodynamic status to guide management.
2. More patients can be treated as outpatients
- Category A: Asymptomatic PE – safe ED discharge.
- Category B: Symptomatic but low-risk PE – early discharge is generally recommended.
This highlights a shift toward individualized, resource-conscious care.
3. PE Response Teams (PERTs) receive a Class I recommendation
Multidisciplinary PE teams are now strongly recommended to facilitate rapid risk stratification and timely treatment decisions.
4. Anticoagulation updates
- LMWH is preferred over UFH when initial parenteral anticoagulation is needed (unless specific indications for UFH exist).
- DOACs are preferred over warfarin in eligible patients because they reduce recurrent VTE and major bleeding.
5. Advanced reperfusion therapies
Systemic thrombolysis, catheter-directed therapies, mechanical thrombectomy, and surgical embolectomy should be selected according to the new A–E risk categories, with the strongest role in patients with hemodynamic compromise.
6. Extended anticoagulation
Patients with a first unprovoked PE or persistent risk factors should generally continue anticoagulation beyond the initial 3–6 months, after balancing bleeding risk.
7. Long-term follow-up is now emphasized
Patients should be assessed for persistent dyspnea and functional limitation for at least 12 months to detect chronic thromboembolic pulmonary disease (CTEPD) or other post-PE complications.
Take-home message:
The 2026 guideline moves PE management toward precision medicine—replacing outdated terminology, expanding outpatient management for low-risk patients, prioritizing multidisciplinary care, and strengthening long-term follow-up.”

Stay updated with Hemostasis Today.
-
Nov 19, 2026, 22:24Erik Nelson: Low Iron Can Raise A1c without Changing Blood Sugar
-
Nov 19, 2026, 22:23Erwin Loh: Daily Iron Supplementation Reduces Iron-Deficiency Anaemia in Children and Adolescents
-
Nov 19, 2026, 22:22Afifah Sardar: Why Can a Simple Painkiller like Aspirin Make You Bleed More?
-
Nov 19, 2026, 22:16Jonathan Penm: Perioperative Anticoagulation Management and Antithrombotic Stewardship Across 31 Countries
-
Nov 19, 2026, 22:15Salomao V.: Innovation in Hemophilia A Is Also About How Patients Receive Their Treatment
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing